Heart failure oral therapies at discharge are associated with better outcome in acute heart ...
GAYAT, Etienne, Mattia ARRIGO, Simona LITTNEROVÁ, Naoki SATO, Jiří PAŘENICA, Shiro ISHIHARA, Jindřich ŠPINAR, Christian MULLER, Veli-Pekka HARJOLA, Johan LASSUS, Oscar MIRO, Aldo P. MAGGIONI, Khalid F. ALHABIB, Dong-Ju CHOI, Jin Joo PARK, Yuhui ZHANG, Jian ZHANG, James L., Jr. JANUZZI, Katsuya KAJIMOTO, Alain COHEN-SOLAL a Alexandre MEBAZAA. Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study. European Journal of heart Failure. Hoboken: Wiley, roč. 20, č. 2, s. 345-354. ISSN 1388-9842. doi:10.1002/ejhf.932. 2018. |
Další formáty:
BibTeX
LaTeX
RIS
|
Základní údaje | |
---|---|
Originální název | Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study |
Autoři | GAYAT, Etienne (250 Francie, garant), Mattia ARRIGO (756 Švýcarsko), Simona LITTNEROVÁ (203 Česká republika, domácí), Naoki SATO (392 Japonsko), Jiří PAŘENICA (203 Česká republika, domácí), Shiro ISHIHARA (392 Japonsko), Jindřich ŠPINAR (203 Česká republika, domácí), Christian MULLER (756 Švýcarsko), Veli-Pekka HARJOLA (246 Finsko), Johan LASSUS (246 Finsko), Oscar MIRO (724 Španělsko), Aldo P. MAGGIONI (380 Itálie), Khalid F. ALHABIB (682 Saúdská Arábie), Dong-Ju CHOI (410 Korejská republika), Jin Joo PARK (410 Korejská republika), Yuhui ZHANG (156 Čína), Jian ZHANG (156 Čína), James L., Jr. JANUZZI (840 Spojené státy), Katsuya KAJIMOTO (392 Japonsko), Alain COHEN-SOLAL (250 Francie) a Alexandre MEBAZAA (250 Francie). |
Vydání | European Journal of heart Failure, Hoboken, Wiley, 2018, 1388-9842. |
Další údaje | |
---|---|
Originální jazyk | angličtina |
Typ výsledku | Článek v odborném periodiku |
Obor | 30201 Cardiac and Cardiovascular systems |
Stát vydavatele | Spojené státy |
Utajení | není předmětem státního či obchodního tajemství |
Impakt faktor | Impact factor: 12.129 |
Kód RIV | RIV/00216224:14110/18:00102127 |
Organizační jednotka | Lékařská fakulta |
Doi | http://dx.doi.org/10.1002/ejhf.932 |
UT WoS | 000429044500022 |
Klíčová slova anglicky | Acute heart failure; Prognosis; Oral therapy |
Štítky | 14110211, 14119612, EL OK, rivok |
Příznaky | Mezinárodní význam, Recenzováno |
Změnil | Změnila: Soňa Böhmová, učo 232884. Změněno: 10. 2. 2019 13:24. |
Anotace |
---|
Aims Heart failure oral therapies (HFOTs), including beta-blockers (BB), renin-angiotensin system inhibitors (RASi) and mineralocorticoid receptor antagonists, administered before hospital discharge after acute heart failure (AHF) might improve outcome. However, concerns have been raised because early administration of HFOTs may worsen patient's condition. We hypothesized that HFOTs at hospital discharge might be associated with better post-discharge survival.& para;& para;Methods and results The study population was composed of 19 980 AHF patients from the GREAT registry. The primary and secondary and results outcomes were 90-day and 1-year all-cause mortality, respectively. Survival was estimated with univariate and covariate-adjusted Cox proportional hazards regression models for the whole population and after propensity-score matching. HFOTs at discharge were consistently associated with no excess mortality in the unadjusted and adjusted analyses of the whole and matched cohorts. In the matched cohort, BB and RASi at discharge were associated with lower 90-day mortality risks compared to the respective untreated groups [hazard ratio (HR) 0.56, 95% confidence interval (CI) 0.46-0.69; and HR 0.53, 95% CI 0.42-0.66, respectively]. The favourable associations of BB and RASi at discharge with 90-day mortality were present in many subgroups including patients with reduced or preserved left ventricular ejection fraction and persisted up to 1 year after discharge. The combination of RASi and BB was associated with an even lower risk of death than RASi or BB alone.& para;& para;Conclusions Administration of HFOTs at hospital discharge is associated with better survival of AHF patients. |
Návaznosti | |
---|---|
MUNI/A/1365/2015, interní kód MU | Název: Kardiovaskulární systém: od modelu přes terapii k prevenci (Akronym: KAMOTEPRE) |
Investor: Masarykova univerzita, Kardiovaskulární systém: od modelu přes terapii k prevenci, DO R. 2020_Kategorie A - Specifický výzkum - Studentské výzkumné projekty |
VytisknoutZobrazeno: 28. 3. 2024 12:17